// Get Polylux from the official package repository
#import "@preview/touying:0.5.5": *
#import "@preview/fletcher:0.5.1" as fletcher: diagram, node, edge
#import themes.university: *

#import "@preview/numbly:0.1.0": numbly

#show: university-theme.with(
  aspect-ratio: "16-9",
  config-info(
    title: [ä¸‹å‚ä½“å¶ç™ºç¨®ã«ã¤ã„ã¦],
    subtitle: [ãªã‚“ã§é ­éƒ¨CTæ’®ã£ã¦ã‚“ã ã‚ˆï¼],
    author: [Nozomi Niimi],
    date: datetime.today(),
    institution: [æ±äº¬åŒ»ç™‚ã‚»ãƒ³ã‚¿ãƒ¼ç·åˆå†…ç§‘],
    // logo: emoji.school,
  ),
)

// for tall slide
#let tall-slide(body) = touying-slide-wrapper(self => {
  self = utils.merge-dicts(self, config-page(
    width: 33.867cm,
    height: 33.867cm,
  ))
  touying-slide(self: self, body)
})


// == PEGã®å€«ç†çš„é©å¿œ

// #tall-slide[
//   #figure(
//   image("figure/PEG_rirni_tekiou.jpeg", height: 70%)
// )
// ]


#show link: underline

#set heading(numbering: numbly("{1}.", default: "1.1"))

#import fletcher.shapes: diamond


// Make the paper dimensions fit for a presentation and the text larger
#set footnote.entry(clearance: 0.1em, gap: 0.2em)
#show heading:set align(start + top)
#show heading: set text(size: 28pt)
#set align(horizon)

#let lb = linebreak(justify: false)

// å¤§ã¾ã‹ãªã‚²ã‚·ãƒ¥ã‚¿ãƒ«ãƒˆã¨ã—ã¦è‹¥å¹´è€…ã® \ ã€Œç¹°ã‚Šè¿”ã™ç™ºç†±ã¨è…¹ç—›(+é«˜CRP)ã€ã‚’å¿˜ã‚Œãªã„  ä½¿ç”¨ä¾‹

#let refs(body) = {
  set text(size: 8pt)
  align(right, body)
}

// #refs("Dysphagia. 2024;39(5):837-845.") ä½¿ç”¨ä¾‹

#set list(marker: ([â€¢], [â—¦], [ğŸ—¸]))
#let list-counter = counter("list")

#show list: set text(14pt)
#show list: it => {
  list-counter.step()

  context {
    set text(24pt) if list-counter.get().first() == 1
    set text(20pt) if list-counter.get().first() == 2
    set text(16pt) if list-counter.get().first() >= 3
    it
  }
  list-counter.update(i => i - 1)
}

// for main text
#set text(
    lang: "ja",  // è‹±èªã—ã‹ä½¿ã‚ãªã„æ–‡æ›¸ã§ã¯"en"ã¨ã™ã‚‹ï¼ˆã‚‚ã—ãã¯æŒ‡å®šã—ãªã„ï¼‰
    font: ("Calibri", "Noto Serif CJK JP"),  
    // font: (æ—¥æœ¬èªæ–‡å­—ã‚’å«ã¾ãªã„ãƒ•ã‚©ãƒ³ãƒˆ, æ—¥æœ¬èªæ–‡å­—ã‚’å«ã‚€ãƒ•ã‚©ãƒ³ãƒˆ),  ã¨ãªã£ã¦ã„ã‚‹
)

// Use #polylux-slide to create a slide and style it using your favourite Typst functions

#title-slide(authors: ([Nozomi Niimi]))

== ç—‡ä¾‹ 

- 79æ­³å¥³æ€§ã€è‡ªå®…å†…è»¢å€’ã§æ•‘æ€¥æ¬é€
- é ­éƒ¨CTã§ä¸‹å‚ä½“è…ºè…«ã‚’æŒ‡æ‘˜ã•ã‚Œã‚‹
- ä¾é ¼æ–‡ã«ã¦ã€ã€Œå¶ç™ºçš„ã«ä¸‹å‚ä½“è…ºè…«ãŒæŒ‡æ‘˜ã•ã‚Œã¦ãŠã‚Šãã¡ã‚‰ã®ç²¾æŸ»ã‚‚ãŠé¡˜ã„ã—ã¾ã™ã€ã¨


== Sellar massã«ã¤ã„ã¦

- ä¸‹å‚ä½“è…ºè…«ãŒæœ€å¤š
- Rathkeåš¢èƒ
- å°å…ã ã¨é ­è“‹å’½é ­è…«ãªã©

// Todo: è¡¨ãªã©ã„ã‚Œã‚‹

== ä¸‹å‚ä½“è…ºè…«ã®åˆ†é¡

- å¤§ãã•ã§åˆ†ã‘ã‚‹ã®ãŒæœ€ã‚‚é‡è¦
  - 10mmä»¥ä¸Š: macroadenoma
  - 10mmæœªæº€: microadenoma

== ä¸‹å‚ä½“è…ºè…«ã®ç”±æ¥

- å®Ÿè‡¨åºŠçš„ã«ã¯ãƒ›ãƒ«ãƒ¢ãƒ³ç”£ç”Ÿã§åˆ†ã‘ã‚‹ã®ãŒè‰¯ã„
  - Prolactinoma
  - GHç”£ç”Ÿè…«ç˜
  - ACTHç”£ç”Ÿè…«ç˜
  - TSHç”£ç”Ÿè…«ç˜
  - éæ©Ÿèƒ½æ€§è…«ç˜(non-functioning pituitary adenoma: NFPA)

== ä¸‹å‚ä½“å¶ç™ºç¨®ã¨ã¯

- ä¸‹å‚ä½“ã«å¶ç™ºçš„ã«è¦‹ã¤ã‹ã£ãŸçµç¯€ã‚’â€ä¸‹å‚ä½“å¶ç™ºç¨®â€ã¨è¨€ã†
  - ãã®ãŸã‚ã€å³å¯†ã«ã¯ä¸‹å‚ä½“è…ºè…«ä»¥å¤–ã‚‚å«ã‚€(7-8å‰²ã¯è…ºè…«ã€æ¬¡ã¯Rathkeåš¢èƒ)
- å¾®å°ã®ä¸‹å‚ä½“çµç¯€ã¯çµæ§‹Common
  - ç„¡é–¢ä¿‚ã®ç†ç”±ã§MRIã‚’æ’®åƒã—ãŸã†ã¡ã€microadenomaã¯10-38%
  - macroadenomaã¯0.2%
  - Autopsyã ã¨æ—¥æœ¬äººã®ã†ã¡18%ç¨‹åº¦ã®æœ‰ç—…ç‡ã¨è¨€ã‚ã‚Œã¦ã„ã‚‹
    - æ—¥æœ¬ã§ã®1000äººã®é€£ç¶šã™ã‚‹Autopsyæ‚£è€…ã§ã¯178äººã«IncidentalomaãŒã‚ã‚Šã€ãã®ã†ã¡34%ãŒ2mmä»¥ä¸Š
    - Adenomaã¨HyperplasiaãŒ20äºº(11%)
    - 37äºº(21%)ãŒRathkeåš¢èƒ
    - æ¢—å¡ãŠã‚ˆã³å‡ºè¡€ãŒãŠã®ãŠã®2äºº(1%)

#refs("Radiology. 1994;193(1):161-164. doi:10.1148/radiology.193.1.8090885
")

== ä¸‹å‚ä½“å¶ç™ºç¨®ã‚’èªã‚‹ä¸Šã§é‡è¦ãªè¦–ç‚¹

- ä¸Šè¨˜ã®é€šã‚Šã€Incidentalomaã¯å®Ÿã¯å¤šã„
- ãã®ç‚ºã€æ‚‰çš†èª¿æŸ»ã¯åŸºæœ¬çš„ã«ã¯ç„¡ç†
- ã‹ã¤ã€åˆ†é¡ã‚„ä¸‹å‚ä½“è…ºè…«ã®ç¨®é¡ã¯æœ¬æ¥ã¯Opeã—ãªã„ã¨åˆ†ã‹ã‚‰ãªã„
- â‡’ ä¸‹å‚ä½“è…ºè…«ã®ç–«å­¦ã¯ãã®è‡¨åºŠç¾å ´ \ (è¦‹ã¤ã‹ã£ãŸç†ç”±ã‚„Opeã‚’ã—ãŸã‹ãªã©)ã«ä¾å­˜ã™ã‚‹

== ç–«å­¦

- Incidentalomaã¨é€šå¸¸ã®Adenomaã§ç–«å­¦ãŒå¤‰ã‚ã‚‹
  - é€šå¸¸ã®Pituitary adenomaã®å ´åˆ
    - 53%ãŒProlactinoma
    - #text(size: 28pt, fill: red, weight: "bold")[30%ãŒéæ©Ÿèƒ½æ€§è…ºè…«]
    - 12%ãŒGHç”£ç”Ÿè…«ç˜(somatotropinoma)
    - 4%ãŒACTHç”£ç”Ÿè…«ç˜(Corticotropinoma)
    - 1%ãŒTSHç”£ç”Ÿè…«ç˜(thyrotropinoma)

  - Incidentalomaã®å ´åˆ(ç´„90%ãŒAdenoma)
    - #text(size: 28pt, fill: red, weight: "bold")[ç´„50%ãŒéæ©Ÿèƒ½æ€§è…ºè…«]
    - 10%ãŒGHç”£ç”Ÿè…«ç˜
    - 15%ãŒGonadothropinoma
- Incidentalomaã ã¨ã€éæ©Ÿèƒ½æ€§è…ºè…«ãŒå¤šã„äº‹ã¯æ³¨ç›®ã«å€¤ã™ã‚‹
#refs("J Clin Endocrinol Metab. 2011;96(4):894-904. doi:10.1210/jc.2010-1048")



== Pituitary incidentalomaã‚’è¦‹ãŸã‚‰ãƒ»ãƒ»ãƒ»ãƒ»ãƒ»ãƒ»

- 3ã¤ã®è¦–ç‚¹ã§è€ƒãˆã‚‹
  1. è…«ç˜ã«ã‚ˆã‚‹ãƒ›ãƒ«ãƒ¢ãƒ³éå‰°ç”£ç”Ÿ
  2. è…«ç˜ã«ã‚ˆã‚‹åœ§æ’åŠ¹æœã«ã‚ˆã‚‹ä¸‹å‚ä½“æ©Ÿèƒ½ä¸å…¨
  3. è…«ç˜ã«ã‚ˆã‚‹è¦–äº¤å‰ã®åœ§æ’ã®æœ‰ç„¡

= ãƒ›ãƒ«ãƒ¢ãƒ³éå‰°ç”£ç”Ÿ

== åŸºæœ¬çš„ãªè€ƒãˆæ–¹

- Microincidetanlomaã§ã¯ç¨€ã¨ã•ã‚Œã‚‹
- Macroadenomaå…¨ä½“ã§ã¯ä»¥ä¸‹ã®é€šã‚Š
  - ProlactinomaãŒ53%
  - GHç”£ç”ŸãŒ12%
  - ACTHç”£ç”ŸãŒ4% 
  - TSHç”£ç”ŸãŒ1%
- é »åº¦ã¨æ²»ç™‚å¯èƒ½æ€§ã®è¦³ç‚¹ã§è€ƒãˆã‚‹
  - PRLã¯#text(fill: red, weight: "bold")[å†…ç§‘çš„ã«æ²»ç™‚å¯èƒ½]
  - ACTH, GHã¯#underline[*äºˆå¾Œä¸è‰¯ã§æ‰‹è¡“ã®æ²»ç™‚é©å¿œ*]
- PRL, ACTH, GHã¯æ¤œç´¢ã™ã¹ã—ï¼ï¼

#refs("JAMA. 2023;329(16):1386-1398. doi:10.1001/jama.2023.5444")

== ãƒ›ãƒ«ãƒ¢ãƒ³éå‰°ç”£ç”Ÿã®å„è«–

- #link(<hyperprl>)[
   é«˜PRLè¡€ç—‡: ãƒ«ãƒ¼ãƒãƒ³ã§æ¤œæŸ»
  ]

- #link(<cushing>)[
   Cushing syndrome: ãƒ«ãƒ¼ãƒãƒ³ã§æ¤œæŸ»(?)
  ]

- #link(<hypergh>)[
   å…ˆç«¯å·¨å¤§ç—‡(GH excess): ãƒ«ãƒ¼ãƒãƒ³ã§æ¤œæŸ»
  ]

- #link(<hypertsh>)[
   ä¸­æ¢æ€§ç”²çŠ¶è…ºæ©Ÿèƒ½äº¢é€²ç—‡: ãƒ«ãƒ¼ãƒãƒ³ã§ã¯è¡Œã‚ãªã„
  ]

== é«˜PRLè¡€ç—‡ #label("hyperprl")


- PRL > 250 mcg/Lã¯ç‰¹ç•°åº¦100ï¼…ã§Prolactinoma
- ä¸€æ–¹ã§ä¸­é€”åŠç«¯ãªé«˜å€¤ã¯è‰²ã€…ãªç†ç”±ãŒã‚ã‚‹
  - å¦Šå¨ ã€è–¬å‰¤(D2 blocker)ã‚„ç”²çŠ¶è…ºæ©Ÿèƒ½ã‚’ç¢ºèªã™ã‚‹
- æ›´ã«ä¸‹å‚ä½“è…ºè…«è‡ªèº«ã®èŒéƒ¨åœ§è¿«ã«ã‚ˆã‚‹ã‚‚ã®(Stalk effect)ã®ã‚‚ã‚ã‚Šã†ã‚‹
  - Stalk effectã ã‘ã§ã¯PRL < 150 mcg/Lç¨‹åº¦ã§ã‚ã‚‹äº‹ãŒå¤šã„
#refs("JAMA. 2023;329(16):1386-1398. doi:10.1001/jama.2023.5444")

== Cushing syndrome #label("cushing")

- 2011å¹´ã®ãƒ¨ãƒ¼ãƒ­ãƒƒãƒ‘ã®ã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ã ã¨å®Ÿã¯ãƒ«ãƒ¼ãƒãƒ³æ¤œæŸ»ã§ã¯ãªã„ \ (è‡¨åºŠçš„ã«ç–‘ã£ãŸæ™‚ã®ã¿)
#refs("J Clin Endocrinol Metab. 2011;96(4):894-904. doi:10.1210/jc.2010-1048")
- å€‹äººçš„ã«ã¯ã€Macroadenomaãªã‚‰ã°ãƒ«ãƒ¼ãƒãƒ³ã§è¡Œã†ã¹ãã¨è€ƒãˆã‚‹
- 3ç¨®é¡ã®æ–¹æ³•ãŒã‚ã‚‹ãŒã€ä¸€ç•ªç°¡å˜ãªã®ã¯LDST
  - LDST(1mg Dexè² è·è©¦é¨“)ï¼šæ„Ÿåº¦98.6%, ç‰¹ç•°åº¦90.6%
  - 24æ™‚é–“è“„å°¿ã®Free cortisol:æ„Ÿåº¦94%, ç‰¹ç•°åº¦93%
  - å¤œé–“å”¾æ¶²ä¸­cortisolï¼šæ„Ÿåº¦95.8%, ç‰¹ç•°åº¦93.4%

== å…ˆç«¯å·¨å¤§ç—‡(GH excess) #label("hypergh")

- GHã®å€¤ã ã‘ã§ã¯è¨ºæ–­å‡ºæ¥ãªã„
- IGF-1ï¼šå¹´é½¢èª¿æ•´ã•ã‚ŒãŸCutoffã§æ„Ÿåº¦ã€ç‰¹ç•°åº¦ã¯ã»ã¼100% \ (12-18æ­³ã€å¦Šå©¦ä»¥å¤–)
- OGTTæ¤œæŸ»ã§GH â‰§0.4 mcg/L(æŠ‘åˆ¶ã•ã‚Œãªã„)ã¯ \ æ„Ÿåº¦85-90%, ç‰¹ç•°åº¦ã¯95%ã‚’è¶…ãˆã‚‹

== ä¸­æ¢æ€§ç”²çŠ¶è…ºæ©Ÿèƒ½äº¢é€²ç—‡ #label("hypertsh")

- TSHéå‰°ç—‡ã®æ¤œæŸ»ã¯ãƒ«ãƒ¼ãƒãƒ³ã§ã¯è¡Œã‚ãªã„
  - ãŸã ã—ã€ãƒ›ãƒ«ãƒ¢ãƒ³æ¬ ä¹ã¨ã‹è€ƒãˆã‚‹ã¨çµå±€æ¤œæŸ»ã—ã¦ã„ã‚‹
- è¡€æ¸…FT4ãŒé«˜å€¤ã§ã€TSHãŒä¸é©åˆ‡ã«æ­£å¸¸å€¤ï½é«˜å€¤ã ã¨æ„Ÿåº¦ã¯ã»ã¼100%

== ã„ã¤ã€ã©ã®ã‚ˆã†ã«æ¤œæŸ»ã‚’ã™ã‚‹ï¼Ÿ

- ãƒ›ãƒ«ãƒ¢ãƒ³éå‰°ã«ã¤ã„ã¦ã€Macroadenomaã«ãŠã„ã¦ã‚‚æ˜ã‚‰ã‹ãªScreeningæ–¹æ³•ã¯æ±ºã¾ã£ã¦ã„ãªã„
  - 2011å¹´ã®ã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ã§ã¯ã€PRLã¨GHã¯ãƒ«ãƒ¼ãƒãƒ³ã§æ¸¬å®šã‚’æ¨å¥¨ã€‚\ ACTHã¯è‡¨åºŠæ‰€è¦‹ã‚’ã¿ã¦ã®æ¤œæŸ»ã‚’æ¨å¥¨ã—ã¦ã„ã‚‹ã€‚
    - PRLã¯çµŒå£ã§ã®æ²»ç™‚ãŒå¯èƒ½ãªãŸã‚
    - GHéå‰°ç”£ç”Ÿã¯äºˆå¾Œã«å¼·ãå½±éŸ¿ã™ã‚‹ä¸Šã«åˆæœŸã¯ç„¡ç—‡å€™ã§ã‚ã‚‹äº‹ãŒå¤šã„ãŸã‚
    - ACTHã‚‚åŒã˜ç†ç”±ã§Expertã«ã‚ˆã£ã¦ã¯æ¤œæŸ»ã‚’ã™ã‚‹ã¨ã®äº‹
  - Reviewè«–æ–‡ã ã¨ä¸‹å‚ä½“ã®ãƒ›ãƒ«ãƒ¢ãƒ³éå‰°ç”£ç”Ÿã¯Prolactin, IGF-1ã®æ¸¬å®šã§ \ é™¤å¤–ã™ã¹ãã¨ã®è¨˜è¼‰ã‚ã‚Š
  - Uptodateã ã¨PRLã€IGF-1ã€LHã€FSHã€ACTHã€24æ™‚é–“å°¿ä¸­Cortisolæ¨å¥¨

#refs(
  "Best Pract Res Clin Endocrinol Metab. 2019;33(2):101268. doi:10.1016/j.beem.2019.04.002
  Peter J Snyder, MD. Pituitary incidentalomas. In: UpToDate, Connor RF (Ed), Wolters Kluwer. Accessed August 15, 2025. https://www.uptodate.com.")

= ä¸‹å‚ä½“æ©Ÿèƒ½ä¸å…¨

== ä¸‹å‚ä½“æ©Ÿèƒ½ä¸å…¨ç·è«–

- Micro incidentalomaã§ã®ä¸‹å‚ä½“æ©Ÿèƒ½ä¸å…¨ã¯7-66%ã§Macroincidentalomaã§ã¯19-46%ã¨ã•ã‚Œã‚‹
  - Hypogonadismã¯ï½30%
  - å‰¯è…ä¸å…¨ã¯ï½18%
  - ç”²çŠ¶è…ºæ©Ÿèƒ½ä½ä¸‹ã¯ï½28%
  - GHæ¬ ä¹ã¯ï½8%
- è…«ç˜åœ§è¿«ã«ã‚ˆã‚‹ä¸‹å‚ä½“æ©Ÿèƒ½ä½ä¸‹ã®ä¸€èˆ¬è«–ã¨ã—ã¦
  - GH, FSH, LHâ†“ â†’ TSHâ†“ â†’ ACTHâ†“ 
    - å‰¯è…ä¸å…¨ãŒã‚ã‚‹æ™‚ã¯æ±ä¸‹å‚ä½“æ©Ÿèƒ½ä½ä¸‹ç—‡ã‚’ç–‘ã†
- 2011å¹´ã®ã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ã ã¨Class Iã§ãƒ›ãƒ«ãƒ¢ãƒ³æ¬ ä¹ã®æ¤œæŸ»ã®æ¨å¥¨
#refs("ç«¹å†…é–åšãƒ»ç«¹ä¸‹å½°ãƒ»è¾°å³¶å•“å¤ªç·¨è‘—(2020).è™ã®é–€ç—…é™¢å†…åˆ†æ³Œã‚¯ãƒªãƒ‹ã‚«ãƒ«ãƒ—ãƒ©ã‚¯ãƒ†ã‚£ã‚¹â€•å¤–æ¥ãƒ»å…¥é™¢ã‹ã‚‰ãƒ•ã‚©ãƒ­ãƒ¼ã‚¢ãƒƒãƒ—ã¾ã§.ã‚¯ãƒªãƒ‹ã‚³å‡ºç‰ˆ
J Clin Endocrinol Metab. 2011;96(4):894-904. doi:10.1210/jc.2010-1048")
  
== ä¸‹å‚ä½“æ©Ÿèƒ½ä¸å…¨ç·è«–

- ç”Ÿå‘½äºˆå¾Œã‚’æ‚ªåŒ–ã•ã›ã‚‹ãƒ›ãƒ«ãƒ¢ãƒ³ã‚’é‡ç‚¹çš„ã«ã¿ã‚‹
  - å‰¯è…ä¸å…¨
  - ç”²çŠ¶è…ºæ©Ÿèƒ½ä½ä¸‹ç—‡
- ä¸€æ–¹ã§ã€Hypogonadismã‚„GHæ¬ ä¹ã¯æˆäººã ã¨æ²»ç™‚é©å¿œã‚‚é›£ã—ã„
=> è¦‹ã‚‹ã¹ãã¯ã€*å‰¯è…ä¸å…¨ã€ç”²çŠ¶è…ºæ©Ÿèƒ½ä½ä¸‹ç—‡*
- JAMAã®Reviewã ã¨ã€æ¤œæŸ»ã¯ã¾ãšã¯è¿…é€ŸACTHè©¦é¨“ã€ä¸­æ¢æ€§TSHæ¬ ä¹ã®ç¢ºèªã€æ¬¡ã«ä¸­æ¢æ€§Hypogonadismã‚’æ¨å¥¨ã€‚
  - GHæ¬ ä¹ã¯ä¸‹å‚ä½“è…ºè…«ã®æ²»ç™‚ãŒçµ‚ã‚ã‚Šä»–ã®ãƒ›ãƒ«ãƒ¢ãƒ³è£œå……ãŒçµ‚ã‚ã£ãŸã‚ã¨ã¾ã§ã¯æ¤œæŸ»ã—ãªã„äº‹ã‚’æ¨å¥¨ã€‚

== ä¸‹å‚ä½“æ©Ÿèƒ½ä¸å…¨å„è«–

- #link(<adrenal_insuf>)[
  ä¸­æ¢æ€§å‰¯è…ä¸å…¨: ãƒ«ãƒ¼ãƒãƒ³ã§æ¤œæŸ»
  ]

- #link(<hypothyroid>)[
  ä¸­æ¢æ€§ç”²çŠ¶è…ºæ©Ÿèƒ½ä½ä¸‹: ãƒ«ãƒ¼ãƒãƒ³ã§æ¤œæŸ»
  ]

- #link(<GH_def>)[
  GHæ¬ ä¹: ãƒ«ãƒ¼ãƒãƒ³ã§æ¤œæŸ»
  ]

- #link(<hypogonado>)[
  Hypogonadism: ãƒ«ãƒ¼ãƒãƒ³ã§æ¤œæŸ»
  ]

- #link(<prolactin_def>)[
  Prolactinæ¬ ä¹: ãƒ«ãƒ¼ãƒãƒ³ã§ã¯è¡Œã‚ãªã„
  ]

- #link(<central_di>)[
  ä¸­æ¢æ€§å°¿å´©ç—‡: ãƒ«ãƒ¼ãƒãƒ³ã§æ¤œæŸ»
  ]

== ä¸­æ¢æ€§å‰¯è…ä¸å…¨ #label("adrenal_insuf")

- Insulin tolerance test (ITT) ãŒæœ€ã‚‚ä¿¡é ¼ã§ãã‚‹æ¤œæŸ»ã ãŒä½¿ã„ã«ãã„
- æ—©æœCortisolãŒç¬¬ä¸€
  - ã¾ãšã¯ã€8-9æ™‚ã®è¡€æ¸…Cortisolã‚’æ¸¬å®šã™ã‚‹
    - cortisol < 80 nmol/L (3 mcg/dL)ã¯å‰¯è…ä¸å…¨
    - cortisol < TODO nmol/L (18 mcg/dL)ã¯å‰¯è…ä¸å…¨
- CortisolãŒ3mcg/dL-15mcg/dLã®æ™‚ â†’ ACTHè² è·è©¦é¨“ã‚’è¡Œã†
    - 250mcgã®ACTHã‚’æ³¨å°„ã‚’ã—ã¦30/60åˆ†å¾Œã®CortisolãŒ\<18mcgã§å‰¯è…ä¸å…¨
    - äºŒæ¬¡æ€§å‰¯è…ä¸å…¨ã®å ´åˆé€šå¸¸ACTHã¯< 12 pmol/L (52 pg/mL)ã¨ãªã‚‹.



== ä¸­æ¢æ€§ç”²çŠ¶è…ºæ©Ÿèƒ½ä½ä¸‹ #label("hypothyroid")

- ä½T4ã«ã‚‚é–¢ã‚ã‚‰ãšä¸é©åˆ‡ã«ä½å€¤ï½æ­£å¸¸ç¯„å›²ã®TSHã®ã¨ãã«ç–‘ã†
- ç‰¹ã«æ·±ãè€ƒãˆãªã„ã§ã‚‚è‰¯ã„
- ã‚‚ã—ã‚‚ã€NTIã¨åŒºåˆ¥ãŒé›£ã—ã„ã¨ãã¯æ™‚é–“ã‚’ã‚ã‘ã¦å†æ¤œæŸ»ãŒç¾å®Ÿçš„

== GHæ¬ ä¹ #label("GH_def")


- GHæ¬ ä¹ã¯äº‹å‰ç¢ºç‡ãŒé«˜ã„çŠ¶æ…‹ã§ã®ã¿ç–‘ã†(é«˜ã„äº‹å‰ç¢ºç‡ã¨ã¯ä»¥ä¸‹ã®åŸºæº–ã®ã†ã¡1ã¤ä»¥ä¸Šã‚’æº€ãŸã™)
  - è‹¥ã„ç”·æ€§ã§æ­£å¸¸ãªä¸‹å‚ä½“ã ãŒä½èº«é•·ã§GHæ¬ ä¹ã®è¨ºæ–­ãŒå¹¼å°‘æœŸã«ã•ã‚Œã¦ã„ã‚‹
  - ä¸‹å‚ä½“ã®éšœå®³ãŒç–‘ã‚ã‚Œã‚‹ç—…æ­´(ä¸‹å‚ä½“æ‰‹è¡“ã€æ”¾å°„ç·šæ²»ç™‚ã€ä¸‹å‚ä½“ã®ç”»åƒå¤‰åŒ–ã€é ­éƒ¨å¤–å‚·ã€è„³å’ä¸­)
- ITTãŒGHæ¬ ä¹ã®Gold standardã ãŒä½¿ã„ã«ãã„
  - ãã®ä»–ã¨ã—ã¦ã¯ã€Glucagonåˆºæ¿€è©¦é¨“ã€Macimorelin testã€arginine plus GH-releasing hormone (GHRH) test
  - Dynamedã§ã¯3ã¤ä»¥ä¸Šã®ä¸‹å‚ä½“ãƒ›ãƒ«ãƒ¢ãƒ³æ¬ ä¹ãŒã‚ã‚Šã€å¹´é½¢èª¿æ•´ã•ã‚ŒãŸè¡€æ¸…IGF-1ãŒä½ã„æ™‚ã¯GHä½å€¤ã¨è¨ºæ–­ã—ã¦è‰¯ã„
  #align(center)[
  vs.
]
  - 2011å¹´ã®ã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ã§ã¯ã€IGF-1ä½ä¸‹ã®ã¿ã§GHæ¬ ä¹ã®è¨ºæ–­ã¯å‡ºæ¥ãªã„


== Hypogonadism #label("hypogonado")

- ç”·æ€§ã€å¥³æ€§(é–‰çµŒå‰/å¾Œ)ã§æ–¹æ³•ãŒç•°ãªã‚‹ã€‚
- ã‚´ãƒŠãƒ‰ãƒˆãƒ­ãƒ”ãƒ³æ”¾å‡ºãƒ›ãƒ«ãƒ¢ãƒ³ï¼ˆGnRHï¼‰åˆºæ¿€æ¤œæŸ»ã¯ã€åŸºç¤ãƒ›ãƒ«ãƒ¢ãƒ³æ¤œæŸ»ã®çµæœãŒã¯ã£ãã‚Šã—ãªã„å ´åˆã«ã‚´ãƒŠãƒ‰ãƒˆãƒ­ãƒ”ãƒ³æ¬ ä¹ç—‡ã®è¨ºæ–­ã«ç”¨ã„ã‚‰ã‚Œã¦ããŸãŒã€å›½éš›çš„ãªå†…åˆ†æ³Œå­¦ä¼šã§ã¯æ¨å¥¨ã•ã‚Œã¦ã„ãªã„ã€‚

== Hypogonadism å„è«–
- ç”·æ€§
  - æ—©æœ(å¯èƒ½ãªã‚‰7-11æ™‚å‰ã§ç©ºè…¹)ã®Total testosteroneã‚’æœ€åˆã«è¡Œã†
    - Total testosteroneãŒ300ng/dLæœªæº€ã§ã€FSH, LHãŒ2å›ã¨ã‚‚ä½ã„ã‹æ­£å¸¸ã§ã‚ã‚Œã°ã€ã‚´ãƒŠãƒ‰ãƒˆãƒ­ãƒ”ãƒ³æ¬ ä¹ç—‡ã¨è¨ºæ–­å¯èƒ½
    - Total testosterone < 231 ng/dLã¯Testosteroneæ¬ ä¹
    - Total testosterone > 231 ng/dLã‹ã¤< 346 ng/dLã§ã¯è¿½åŠ ã®æ¤œæŸ»(free or bioavailable testosterone)ã‚’è€ƒæ…®ã™ã‚‹
    - Total testosterone level â‰¥ 346 ng/dLã¯Testosteroneæ­£å¸¸ã¨è€ƒãˆã¦è‰¯ã„
- é–‰çµŒå‰å¥³æ€§: ç„¡æœˆçµŒã‚ã‚‹ã„ã¯æœˆçµŒä¸é †ãŒã‚ã‚Šã€E2ä½å€¤ãŠã‚ˆã³ä½å€¤ï½æ­£å¸¸å€¤ã®FSHã¨LHã ã¨è¨ºæ–­å¯èƒ½
- é–‰çµŒå¾Œå¥³æ€§: FSH, LHãŒé«˜å€¤ã§ãªã„ã ã‘ã§ã»ã¼è¨ºæ–­å¯èƒ½
  - ç”²çŠ¶è…ºç•°å¸¸ã‚„PRLé«˜å€¤ã«ã¤ã„ã¦äº‹å‰ã«é™¤å¤–ã™ã‚‹
  

== Prolactinæ¬ ä¹ #label("prolactin_def")

- è¡€æ¸…PRLãŒ< 100 pmol/Lã®æ™‚ã«æ¬ ä¹ã‚’ç¤ºå”†ã™ã‚‹

== ä¸­æ¢æ€§å°¿å´©ç—‡ #label("central_di")

- è™ãƒé–€ã®æ•™ç§‘æ›¸ã§ã¯ä¸­æ¢æ€§å°¿å´©ç—‡ã¯è¡“å¾Œã§ãªã„é™ã‚Šä¸‹å‚ä½“è…ºè…«ã§ã¯èµ·ããªã„ã¨ã®äº‹
- è¨ºæ–­ã®Gold standardã¯å­˜åœ¨ã—ãªã„
- æ°´åˆ¶é™è©¦é¨“ãŒã—ã°ã—ã°åˆæœŸã®æ¤œæŸ»ã§è¡Œã‚ã‚Œã‚‹
  - æ°´åˆ†åˆ¶é™è©¦é¨“ã®äºœç¨®ã¨ã—ã¦ã€3%é£Ÿå¡©æ°´åˆºæ¿€è©¦é¨“ãŒã‚ã‚‹
  - å¤šå°¿ (> 50 mL/kg in 24 hours or 3.5 L/day in a 70kg) ã®æ™‚ã«è¡€æ¸…ã¨å°¿ä¸­æµ¸é€åœ§ã‚’åŒæ™‚æ¸¬å®šã™ã‚‹
  - å°¿ç³–ãªã—ã®æ™‚ã«ã€è¡€æ¸…æµ¸é€åœ§ >295 mOsm/kgã€å°¿æµ¸é€åœ§ãŒ600 mOsm/kgã®æ™‚(å°¿ã¨è¡€æ¸…æµ¸é€åœ§ã®æ¯”ãŒ2ä»¥ä¸Š)ãŒæ­£å¸¸
  - å°¿å´©ç—‡ã¯è¡€æ¸…æµ¸é€åœ§ >295 mOsm/kgã®æ™‚ã«å°¿æµ¸é€åœ§ãŒ600 mOsm/kgæœªæº€ã®æ™‚(å°¿ã¨è¡€æ¸…æµ¸é€åœ§ã®æ¯”ãŒ2æœªæº€)ã§è¨ºæ–­ã•ã‚Œã‚‹

== ã„ã¤ã€ã©ã®ã‚ˆã†ã«æ¤œæŸ»ã‚’ã™ã‚‹ï¼Ÿ

- ãƒ›ãƒ«ãƒ¢ãƒ³ä½ä¸‹ã«ã¤ã„ã¦ã€è¤‡æ•°ã®Screeningæ–¹æ³•ãŒã‚ã‚Šç¢ºå®šçš„ãªã‚‚ã®ã¯ãªã„ã€‚
  - 2011å¹´ã®ã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ã§ã¯æ„è¦‹ã‚’2ã¤è¼‰ã›ã¦ã„ã‚‹
    - Minimal: FT4, æœã®Cortisolã¨Testosterone
    - è¿½åŠ : FT4, æœã®Cortisolã¨Testosteroneã«åŠ ãˆã¦TSHã€LH, FSH, IGF-1
    - ACTHã¨GHæ¬ ä¹ãŒBaselineã®æ¤œæŸ»ã§ç¢ºå®šã§ããªã„æ™‚ã«è² è·è©¦é¨“ã‚’è€ƒæ…®ã™ã‚‹ã€‚
  - Microadenomaã ã¨ã‚ˆã‚Šåˆ†ã‹ã£ã¦ã„ãªã„ã€‚Uptodateã ã¨PRLã ã‘æ¨å¥¨ã ãŒ2011å¹´ã®Endocrine Society Guidelineã¨ã¯ç•°ãªã‚‹ã€‚

== è¦–é‡éšœå®³ã«ã¤ã„ã¦

- MRIã§Optic Chiasmã® compressionãŒã‚ã‚‹å ´åˆã¯è‡ªè¦šç—‡çŠ¶ãŒãªãã¦ã‚‚ã€\ Goldmanè¦–é‡æ¤œæŸ»ãªã©ã®æ­£å¼ãªè¦–é‡éšœå®³ã®è©•ä¾¡ã‚’è¡Œã†
  
#refs("Clin Med. 2023;23(2):129-134. doi:10.7861/clinmed.2023-0020
J Clin Endocrinol Metab. 2011;96(4):894-904. doi:10.1210/jc.2010-1048")


= æ²»ç™‚æ³•

== æ²»ç™‚æ³•ç·è«–

- Cushing syndromeã€æœ«ç«¯è‚¥å¤§ç—‡ã¯å¤–ç§‘æ²»ç™‚ãŒå¿…è¦
- 2011å¹´ã®ã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ã§ã¯ã€incidentalomaã§ã‚‚ãƒ›ãƒ«ãƒ¢ãƒ³åˆ†æ³Œéšœå®³ãŒã‚ã‚‹ã¨ãã¯æ‰‹è¡“ã‚’è€ƒæ…®ã™ã‚‹ã¨ã®è¨˜è¼‰ã‚ã‚Š(class 2)
  
== Follow up

- éæ©Ÿèƒ½æ€§ä¸‹å‚ä½“è…«ç˜ã®å ´åˆã€çµŒéè¦³å¯Ÿã§è‰¯ã„ã€‚MRIã¯6ï¼12ãƒ¶æœˆå¾Œã«è¡Œã„Mass effectsãªã©ã‚’ç¢ºèªã™ã‚‹ã€‚
-  Hypopituitarismã«ã¤ã„ã¦ã¯åŠå¹´å¾Œã«è¡Œã„ã€ãã®å¾Œã¯1æ¯ã«è¡Œã†

== å‚è€ƒæ–‡çŒ®

#block[
  #set text(size: 12pt)

1. ç«¹å†…é–åšãƒ»ç«¹ä¸‹å½°ãƒ»è¾°å³¶å•“å¤ªç·¨è‘—(2020).è™ã®é–€ç—…é™¢å†…åˆ†æ³Œã‚¯ãƒªãƒ‹ã‚«ãƒ«ãƒ—ãƒ©ã‚¯ãƒ†ã‚£ã‚¹â€•å¤–æ¥ãƒ»å…¥é™¢ã‹ã‚‰ãƒ•ã‚©ãƒ­ãƒ¼ã‚¢ãƒƒãƒ—ã¾ã§.ã‚¯ãƒªãƒ‹ã‚³å‡ºç‰ˆ
2. Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4):894-904. doi:10.1210/jc.2010-1048 
3. Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4):894-904. doi:10.1210/jc.2010-1048 
4. Teramoto A, Hirakawa K, Sanno N, Osamura Y. Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology. 1994;193(1):161-164. doi:10.1148/radiology.193.1.8090885 
5. American College of Physicians. ACP MKSAP: Medical Knowledge Self-Assessment Program. American College of Physicians; 2025. https://www.acponline.org/featured-products/acp-mksap
6. DynaMed. Sellar Mass - Approach to the Patient. EBSCO Information Services. Accessed 2025å¹´8æœˆ2æ—¥. https://www.dynamed.com/approach-to/sellar-mass-approach-to-the-patient
7. Boguszewski CL, de Castro Musolino NR, Kasuki L. Management of pituitary incidentaloma. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101268. doi:10.1016/j.beem.2019.04.002 
8. Lee SY, Pearce EN. Hyperthyroidism: A Review. JAMA. 2023;330(15):1472-1483. doi:10.1001/jama.2023.19052 
9. Peter J Snyder, MD. Pituitary incidentalomas. In: UpToDate, Connor RF (Ed), Wolters Kluwer. Accessed August 15, 2025. https://www.uptodate.com. 
10. Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4):894-904. doi:10.1210/jc.2010-1048
]
